234 related articles for article (PubMed ID: 18345032)
1. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.
Aghi M; Visted T; Depinho RA; Chiocca EA
Oncogene; 2008 Jul; 27(30):4249-54. PubMed ID: 18345032
[TBL] [Abstract][Full Text] [Related]
2. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.
Peters C; Paget M; Tshilenge KT; Saha D; Antoszczyk S; Baars A; Frost T; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2018 Aug; 92(15):. PubMed ID: 29793956
[TBL] [Abstract][Full Text] [Related]
3. Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.
Kanai R; Zaupa C; Sgubin D; Antoszczyk SJ; Martuza RL; Wakimoto H; Rabkin SD
J Virol; 2012 Apr; 86(8):4420-31. PubMed ID: 22345479
[TBL] [Abstract][Full Text] [Related]
4. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
5. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
7. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Wakimoto H; Kesari S; Farrell CJ; Curry WT; Zaupa C; Aghi M; Kuroda T; Stemmer-Rachamimov A; Shah K; Liu TC; Jeyaretna DS; Debasitis J; Pruszak J; Martuza RL; Rabkin SD
Cancer Res; 2009 Apr; 69(8):3472-81. PubMed ID: 19351838
[TBL] [Abstract][Full Text] [Related]
8. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
9. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
10. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.
Gambini E; Reisoli E; Appolloni I; Gatta V; Campadelli-Fiume G; Menotti L; Malatesta P
Mol Ther; 2012 May; 20(5):994-1001. PubMed ID: 22354378
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
12. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
Menotti L; Nicoletti G; Gatta V; Croci S; Landuzzi L; De Giovanni C; Nanni P; Lollini PL; Campadelli-Fiume G
Proc Natl Acad Sci U S A; 2009 Jun; 106(22):9039-44. PubMed ID: 19458262
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.
Nakashima H; Nguyen T; Kasai K; Passaro C; Ito H; Goins WF; Shaikh I; Erdelyi R; Nishihara R; Nakano I; Reardon DA; Anderson AC; Kuchroo V; Chiocca EA
Clin Cancer Res; 2018 Jun; 24(11):2574-2584. PubMed ID: 29511029
[No Abstract] [Full Text] [Related]
16. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
17. Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo.
Mehta H; Muller J; Markovitz NS
J Virol; 2010 Nov; 84(21):10982-90. PubMed ID: 20702618
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L; Wakimoto H
Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
[TBL] [Abstract][Full Text] [Related]
19. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
20. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]